Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

China Sky One Soars after Releasing Strong 2008 Results

publication date: Apr 16, 2009

China Sky One Medical (中国天字一号医药公司) announced 2008 financial results that were a significant advance over 2007 and also slightly ahead of forecasts. In 2008, the company’s revenues increased 86% to $91.8 million, while net income rose 88% to $35.7 million or $1.87 per share, fully diluted. China Sky One expects its business will continue to grow: it issued 2009 guidance for revenues in a $128-$130 million range, a 40% jump, and net income of $38-39 million, which is higher by 30%. More details...

Stock Symbol: (NSDQ: CSKI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China